Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navtemadlin alone or with chemotherapy in AML
NCT04113616Phase 2Terminated
- Sponsor
- Kartos Therapeutics
- Start
- Sep 2019
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, open-label trial of navtemadlin in acute myeloid leukemia (AML) (6 arms), sponsored by Kartos Therapeutics. Primary endpoint: Recommended Phase 2 Dose at 28 days. Started Sep 2019; status: terminated.
02
Drugs
navtemadlin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04113616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04113616.